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Abstract
Background: Canine hypoadrenocorticism is an immune-mediated endocrinopathy that shares both clinical and
pathophysiological similarities with Addison’s disease in humans. Several dog breeds are overrepresented in the
disease population, suggesting that a genetic component is involved, although this is likely to be polygenic.
Previous research has implicated CTLA4 as a potential susceptibility gene. CTLA4 is an important regulator of T cell
function and polymorphisms/mutations in CTLA4 have been associated with a number of autoimmune phenotypes
in both humans and rodent models of autoimmunity. The aim of the current study was to undertake a case:control
association study of CTLA4 promotor polymorphisms in three dog breeds, cocker spaniels, springer spaniels and
West Highland white terriers (WHWT).
Results: Polymorphisms in the CTLA4 promoter were determined by PCR and sequence-based typing. There were
significant associations with three promoter haplotypes in cocker spaniels (p = 0.003). A series of SNPs were also
associated with hypoadrenocorticism in cocker spaniels and springer spaniels, including polymorphisms in
predicted NFAT and SP1 transcription factor binding sites.
Conclusions: This study provides further evidence that CTLA4 promotor polymorphisms are associated with this
complex genetic disease and supports an immune mediated aetiopathogenesis of canine hypoadrenocorticism.
Keywords: Addison’s, Canine, CTLA-4, Hypoadrenocorticism, Promoter
Plain English summary
Around one in 500 dogs are affected by Addison’s disease
(hypoadrenocorticism), a lifelong, life threatening, disease
that also less commonly affects humans. Addison’s disease
is caused by a lack of cortisol (stress hormone) and other
hormones due to destruction of the adrenal gland that
makes these hormones. The most common cause of
adrenal gland destruction is autoimmunity, meaning the
body’s immune system attacks its own gland, similar to
type 1 diabetes or rheumatoid arthritis. The reasons why
this happens are not fully understood.
In this study we looked at genetic differences in dogs
specifically in the area controlling expression (promotor
region) of a gene, CTLA4. CTLA4 is vital to immune
system function. Specifically, CTLA4 acts as a brake on
the immune system, so less CTLA4 means less of a
brake and therefore possibly more autoimmunity. We
showed changes in this promotor region are associated
with increased risk of Addison’s in springer spaniels and
cocker spaniels. This highlights CTLA4 as likely one of
the genetic reasons why some dogs get this disease and
others do not.
By better understanding the underlying genetic rea-
sons for Addison’s disease in dogs we aim to be able to
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better help dogs with the disease and hopefully help
understand the human disease better too.
Background
Canine hypoadrenocorticism, in common with human
autoimmune Addison’s disease (hAAD), results from a
deficiency in production of steroid hormones from the
adrenal gland [1]. Clinical signs associated with adrenal
insufficiency are varied and dogs may present in an ‘Ad-
disonian crisis’ with electrolyte disturbances, collapse
and shock. Hypoadrenocorticism is a potentially fatal
disease, which appears to be under diagnosed [2, 3]. The
pathology in the adrenal gland is consistent with an
autoimmune aetiology, characterised, at least in the early
stages, by immune cell infiltration, similar to that seen
in hAAD [2, 4]. Furthermore, circulating autoantibodies,
which can be long lived, have been demonstrated in a
subset of dogs, and are linked to a susceptibility geno-
type [5, 6].
In man, the primary susceptibility locus associated
with hAAD, is the human leukocyte antigen (HLA), encod-
ing major histocompatibility complex (MHC) molecules
[7]. Variation in other immune response genes have also
been shown to be involved in susceptibility to hAAD, in-
cluding the protein tyrosine phosphatase, non-receptor 22
(PTPN22) gene, which is involved in intracellular T cell
receptor signalling [8, 9] and cytotoxic T-lymphocyte-
associated protein 4 (CTLA4) [8, 10]. Due to its important
role in immune regulation and tolerance, CTLA4 been pos-
ited as a general autoimmune susceptibility locus by several
authors [10–13]. CTLA4 polymorphisms have been exten-
sively studied in the human population and consistent asso-
ciations have been found with hAAD [14–16] including a
Europe-wide meta-analysis which demonstrated a signifi-
cant association between hAAD and a SNP in exon 1,
within the signal peptide of the coding sequence [17] and
associations with a promoter polymorphism and hAAD in
the Norwegian population [16, 18]. However, the rela-
tionship between CTLA4 polymorphisms and hAAD
is not found in all ethnic groups [14, 19] and it is
likely that within different populations, different poly-
morphisms exert different effects within a complex
genetic landscape [18, 20].
In dogs, genetic susceptibility to hypoadrenocorticism
has been evidenced through breed predispositions and
further revealed by pedigree analyses [21–26]. More
focussed dissection of underlying genetic factors has
shown dog leukocyte antigen (DLA) class II variation to
be significantly associated with hypoadrenocorticism
[5, 27–29]. Whilst the significance of these findings
have been contested [30, 31] it is the case that fine
mapping techniques have confirmed MHC associa-
tions in human studies as well as revealing further as-
sociations and the importance of epistasis [32].
In early genetic studies of canine hypoadrenocorticism,
microsatellite markers in the vicinity of CTLA4 were
shown to be associated with hypoadrenocorticism in
Portuguese Water Dogs (PWDs) and Nova Scotia duck
tolling retrievers [24, 33]. However, when the sequence
around CTLA4 was analysed in PWDs, three haplotypes
were identified that did not segregate convincingly with
hypoadrenocorticism, although further details were not
provided [24]. More recent candidate gene studies,
undertaken across several breeds, have revealed a SNP
in the CTLA4 promoter region, to be associated with
hypoadrenocorticism in springer spaniels but not in
other breeds [34, 35]. Although there are no reported
SNPs in the canine CTLA4 coding sequence, the pro-
moter region has been characterised in some detail
[36, 37], revealing 20 SNPs and three indels within
the space of 1.6 kB upstream of the start codon.
These variants segregate into 17 distinct haplotypes.
Significant allele and haplotype associations have been
reported between the CTLA4 promoter region and
diabetes [36], although not for immune-mediated
haemolytic anaemia [37]. This high degree of poly-
morphism in the canine CTLA4 promotor has the po-
tential to impact on protein expression, which may,
in turn, influence its immune regulatory function and
susceptibility to autoimmunity. Our hypothesis is that
CTLA4 plays a role in the immunopathogenesis of ca-
nine hypoadrenocorticism and the study aimed to
examine CTLA4 promotor alleles and haplotypes in
selected breeds.
Materials and methods
Samples consisted of the residual volume of blood sam-
ples following completion of diagnostic testing at the
Royal Veterinary College (RVC) Diagnostic Laboratories
(Hertfordshire, UK) or NationWide Laboratories (NWL)
(Poulton-le-Fylde, UK); blood samples were not specific-
ally taken for this study in line with the ethical approval
for the project and United Kingdom law. Furthermore,
due to the nature of the ethical approval for this project
(i.e. submitted samples were required to be de-identified)
and to comply with UK data protection regulations, it was
not possible to explore the relatedness of the animals,
whose DNA samples were genotyped in the study. Further
genomic DNA (gDNA) samples from dogs affected by
hypoadrenocorticism were provided from the UK DNA
Archive for Companion Animals (Universities of Liverpool
and Manchester). A cohort of affected dogs com-
prised the populations described in previous genetic
analyses in hypoadrenocorticism, [34, 35]. The control
(unaffected) dogs are unique to this paper and were
accessed from the RVC Genetic Archive. The cocker
spaniels affected with hypoadrenocorticism are com-
mon to both studies; ten affected springer spaniels
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are unique to this study and four affected WHWT
are unique to this study.
Dogs affected with hypoadrenocorticism were identi-
fied from clinical and diagnostic records with pre- and
post- ACTH stimulation test results consistent with cor-
ticosteroid deficiency (both < 27.6 nmol/L) and no
known history of recent steroid administration. Genomic
DNA from breed matched control dogs over 9 years old
with no known history of endocrinopathy or immune-
mediated disease were selected from the RVC Genetic
Archive. All samples were handled and processed ac-
cording to local laboratory protocols and procedures
until they entered the study at which point they were
stored at − 20 °C in RNase, DNase, DNA and PCR-
inhibitor free polypropylene tubes. Transfer of samples
between locations was performed frozen on dry ice.
The RVC has ethical approval for residual clinical ma-
terial, taken for diagnostic purposes, to be used for re-
search with informed owner consent. NationWide
Laboratories has approval for utilising clinical material
for development of diagnostic assays, provided that ano-
nymity is maintained and data protection is observed.
Extraction of nucleic acid and PCR
Genomic DNA extraction and subsequent PCR was per-
formed as previously described [37]. Briefly, gDNA was
extracted from EDTA blood using the GenElute Blood
Genomic Extraction Kit (Sigma-Aldrich, UK) according
to the manufacturer’s instructions. Polymerase chain re-
action (PCR) was used to amplify the CTLA4 promoter
region (1.6 kb upstream of exon 1) using custom de-
signed primers (CTLA4 promoter sense: 5′-TGCTCC
TCTGTGGCTATGTG-3′ and CTLA4 promoter anti-
sense: 5′-TGAACACTGCTCCATAAAGC-3′) (Fig. 1).
PCR was performed in 50 μL reactions, containing 2 μL
gDNA as template and 4 μL primer mix (20 pmol/μL
total concentration CTLA4 promoter-specific primers).
Each reaction also contained 10 μL Hi-Spec® additive,
5 μL 10x ImmunoBuffer®, 2.5 μL MgCl2 (2.5 mM final
concentration), 0.5 μL dNTP (1 mM final concentration)
and 0.2 μL Immolase® DNA polymerase (2.5 IU) (all Bio-
line). Reactions were heated to 95 °C for 10 min (poly-
merase activation), followed by 35 cycles consisting of
94 °C for 40 s (denaturation), 60 °C for 30 s (annealing)
and 72 °C for 2 min (elongation); with a final extension
step at 72 °C for 10 min. The reactions were performed
using a G-Storm® GS1 Thermal Cycler (Gene Technolo-
gies Ltd., Essex, UK).
PCR products were separated by horizontal gel elec-
trophoresis in 2% agarose dissolved in Tris/borate/
EDTA (TBE) buffer (both from Bioline) containing
1.5 μL/mL SafeView™ Nucleic Acid Stain (NBS Biologi-
cals Ltd., Huntingdon, UK) and visualised under 590 nm
UV light (ImageMaster VDS®, Pharmacia Biotech/GE
Healthcare, Buckinghamshire, UK). Amplicons were
excised and DNA extracted using the GenElute Gel
Extraction Kit (Sigma-Aldrich, UK) according to the
manufacturer’s instructions. PCR products were submit-
ted for Sanger sequencing (Source Bioscience, UK) using
the PCR primers and two additional primers for internal
sequencing (CTLA4 Promoter Sequencing 5′-TCTGTT
TGCCTGTCAGTCTCC-3′ and CTLA4 promoter Se-
quencing 2 5′-TGCAGTTAATGCCTTAAGGGA-3′).
Chromatograms were analysed using BioEdit Sequence
Alignment Editor Software. Previously documented
SNPs and indels were analysed and haplotypes assigned
for each dog (Table 1) [37]. The call rate for all markers
was 100%, achieved through repeat PCR and sequencing
when necessary.
Data were organised in Microsoft® Excel© 2013 version
15 (Microsoft Corporation, Redmond, WA, USA) and
statistical analyses performed using PLINK version 1.071
(Shaun Purcell) and IBM© SPSS© Statistics for Windows,
Version 24.0 (IBM Corp, Armonk, NY, USA). An exact
method was used for the testing of Hardy Weinberg
equilibrium, due to the presence of rare genotypes [38].
Categorical data were analysed using contingency tables,
with Fisher’s exact test used for comparisons. Permutation
testing (10,000 permutations using the max (T) method in
PLINK) was used to correct for multiple testing when
individual markers were assessed. The cut off for signifi-
cance was set at p < 0.05.
Results
Samples from springer spaniels (n = 28 cases, n = 57
controls), cocker spaniels (n = 19 cases, n = 51 controls)
and WHWT (n = 28 cases and n = 31 controls) were
included in the study.
Sex and age information was only available for 10
springer spaniel cases, seven female and three male,
which was not significantly different to the control
population (p = 0.168) comprising of 24 female and 33
male dogs. A significant age difference was found in
springer spaniels (p < 0.001) with controls (572; 468–728
wk) older than cases (364; 156–520 wk). The medical
conditions for which the control population presented
included 15 dogs with a neurological condition, includ-
ing seven with intervertebral disc disease (IVDD) and
three with epilepsy, four dogs had an orthopaedic com-
plaint, four infections, two each with neoplasia, cardiac
disease, chronic renal failure and a toxic insult. Several
dogs had more than one concurrent medical complaint.
Sex and age information was only available for 12 of
the cocker spaniel cases, ten female and two male, which
was significantly different to the control population (p =
0.049) comprised of 23 female and 35 male dogs. A
1http://pngu.mgh.harvard.edu/purcell/plink/
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significant age difference was found found in the cocker
spaniels (p = 0.001) with controls (520; 468–728 wk)
older than cases (286; 156–598 wk). The medical condi-
tions for which the control population presented in-
cluded 20 dogs with neoplasia, 12 with IVDD, six with
cardiac disease, two each with epilepsy and orthopaedic
disease. Several dogs had more than one concurrent
medical complaint.
Sex and age information was only available for 14 of
the WHWT cases, 10 female and four male which was
not significantly different to the control population (p =
0.051) comprised of 11 female and 20 male dogs. A sig-
nificant age difference was found between the WHWT
groups (p < 0.001) with controls (588; 486 – 780wk)
older than cases (217; 13–464 wk). The medical condi-
tions for which the control population presented
included nine dogs with respiratory disease, of which
seven had idiopathic pulmonary fibrosis, five dogs with
renal disease, four with orthopaedic disease, four with
neurological disease and two each with oesophageal
Fig. 1 Canine CTLA4 promoter region variation and selected response elements. Primer binding sites are shown, highlighted yellow with arrow
denoting the starting base in a 5′-3′ direction. Variations are as named, indicated by or ; SNPs highlighted green, Dog Genome Assembly allele
followed by variant shown; INDELs highlighted red, capital letters denote a variant present in, and lowercase letters denote variation not present in, the
dog genome assembly sequence. Predicted response elements NFAT TTTCC (a) highlighted pink; partial SP1 site highlighted turquoise; partial GATA1 site
highlighted blue; predicted AP-1 site highlighted purple; FoxP3 TTTGTT highlighted grey; TCF site highlighted dark green. SNP codes: M: A/C; R: A/G; S: C/
G; Y: C/T; K: G/T. Exon sequence is orange. The ATG start codon is bold double underlined. The TATA box is bold single underlined
Boag et al. Canine Medicine and Genetics             (2020) 7:2 Page 4 of 13
foreign bodies and trauma. Several dogs had more than
one concurrent medical complaint.
Minor allele frequencies are shown in Table 2, show-
ing some degree of disparity between the three breeds.
All variants were in Hardy Weinberg equilibrium for
case, control and whole populations for cocker spaniels
and springer spaniels. For WHWT, 13/23 variants were
not in equilibrium for the case population, whilst being
in equilibrium within the control population (Table 3);
due to this the WHWT haplotypes and nucleotide vari-
ants were not assessed further.
Genotype and haplotype associations
Testing for association of genotype (p = 0.669) and haplo-
type (p = 0.291) with hypoadrenocorticism in springer
spaniels did not reveal any overall significant associations,
although haplotype 2 was overrepresented in post-hoc
testing (Table 4). No effect of homozygosity was found
(p = 0.474). For cocker spaniels, there were significant as-
sociations between disease phenotype and CTLA4 pro-
moter genotype (p = 0.006) with dogs homozygous for
haplotype 8 more likely in controls (43/51) than cases (10/
19) (p = 0.0034) no other significant genotype associations
were found. Cocker spaniel also had significant associa-
tions with haplotype (p = 0.003) with haplotypes 3 (OR =
4.59, p = 0.0247) and 12 (OR = 11.8, p = 0.0193) associated
with increased odds of hypoadrenocorticism and haplo-
type 8 (OR = 0.20, p = 0.0038) associated with decreased
odds of hypoadrenocorticism (Table 5). Cases were more
likely to be heterozygous (p = 0.011).
Specific allele associations
To further elucidate the role of specific polymorphisms
within associated haplotypes in cocker spaniels and to
determine whether any polymorphisms segregated with
hypoadrenocorticism outside full haplotypes in springer
spaniels, SNPs and indels were analysed individually. In
springer spaniels 14/23 markers segregated with disease,
11/14 were in linkage disequilibrium and the minor al-
leles were associated with hypoadrenocorticism (OR
2.16, p = 0.026). Of the further 3/14 markers, for SNP7
(OR = 2.5, p = 0.008) and SNP9 (OR = 2.19, p = 0.027),
the minor allele was associated with hypoadrenocorti-
cism and for indel3, the minor allele was associated with
decreased odds of hypoadrenocorticism (OR = 0.5, p =
0.031) (Table 6). Three markers segregated with
hypoadrenocorticism in the cocker spaniels, with the
minor allele in SNP13 (OR = 11.88, p = 0.016), SNP14
(OR = 3.61, p = 0.031) and indel3 (OR = 4.43, p =
0.006), associated with an increased risk of hypoadre-
nocorticism (Table 7).
Discussion
Within canine hypoadrenocorticism, two previous
studies analysed genetic variants in the region of the
CTLA4 locus [24, 33] and two studies focussed on a
single CTLA4 promoter SNP as a susceptibility
marker (SNP 16 in this study) [34, 35]. This study
was therefore designed to conduct a more detailed
analysis of variation in the CTLA4 promoter region
in dogs with hypoadrenocorticism.
Table 1 CTLA4 promoter haplotypes. Haplotype 3 (*) is the reference haplotype derived from the dog genome assembly sequence
and dog genome assembly SNPs are in shaded cells
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Two populations of dog with hypoadrenocorticism in
this study, cocker spaniels and springer spaniels, overlap
with previous analyses [34, 35]. However, this study has
expanded case populations, novel control populations
and has extended the analysis from a single SNP to a
wider, previously described, promoter region [37]. The
control populations used in this study were selected
based on a more stringent phenotyping compared to
prior studies [34, 35]. Despite a more rigorous inclusion/
exclusion criteria, the phenotyping and selection of
unaffected dogs was still limited by the information
available from the available clinical records. It is pos-
sible that dogs might have had historical or concur-
rent disease(s) not recorded in the electronic patient
record. Incorrect phenotyping in this study would
lead to the erroneous inclusion of individuals with
immune-mediated conditions; which might decrease
the power of this study to identify a difference rather
than bias towards a type one error. In this study the
case phenotyping is robust given the nature of the
diagnostic criteria; however, any incorrect phenotyp-
ing would also bias towards a type two error.
Permutation analysis was used to correct for family-
wise error in this study as well as false discovery rate
correction. Given the analysis of a single locus with sev-
eral highly linked markers, this choice seems appropriate
and caution must be used in interpreting the results.
Genotyping errors from low call rates and missing
samples can limit or bias genetic analyses with these
effects exaggerated in candidate gene studies with rela-
tively small numbers [39]. Every effort was made to
identify and call each polymorphism in this study lead-
ing to a 100% call rate eliminating this as a source of
bias.
The WHWT case population selected for this study
was found not to be in HWE. Inferences of significant
associations with disease can made regarding deviation
from HWE in case but not control populations [40, 41].
However, deviation from HWE can also be caused by a
number of factors, including genotyping errors, popula-
tion stratification and sampling methods. Sampling in
this study was performed through two centres, therefore
population stratification is possible, with local genetic
pools of dogs contributing to these differences. As out-
lined in the methods, no further exploration of related-
ness of dogs was possible. These data should therefore
be interpreted with caution, both due to the small sam-
ple size and possible stratification issues [40]. It remains
possible that the loss of HWE in the case population re-
flects an association of the SNPs and indel2 with
hypoadrenocorticism.
Springer spaniels were not found to have significant
associations between hypoadrenocorticism and genotype,
heterozygosity or haplotypes. Significant associations
were found with several variants, primarily with SNPs
making up haplotype 2 which was overrepresented in
post-hoc haplotype analysis (Table 4). Haplotype 2 only
differs from haplotype 3, overrepresented in the closely
related cocker spaniels with hypoadrenocorticism, by a
G to A substitution at SNP6 (Table 1). The potential sig-
nificance of possibly biologically relevant individual vari-
ants is discussed later.
In cocker spaniels, a homozygous 8/8 genotype was
found to be associated with an absence of hypoadreno-
corticism. Following this, haplotypes 3 and 12 were both
identified as risk haplotypes and haplotype 8 as a pro-
tective haplotype with affected dogs more likely to be
heterozygotic. Haplotype 3 was not identified as a risk
haplotype for diabetes mellitus in a previous study [36].
However, the closely related haplotype 2 was associated
with diabetes mellitus in Border terriers with an opposite
association in West Highland white terriers. Haplotype
12 has not been identified as a risk haplotype previously
but reported as protective for diabetes in Samoyed and
miniature Schnauzers, and neutral in WHWT and cross-
breed dogs. Haplotype 8, a protective haplotype for
Table 2 Minor allele frequencies. SNPs and indels are shown in
5’ to 3’ order from top to bottom
Marker WHWT Springer Spaniel Cocker Spaniel
Minor Allele MAF Minor Allele MAF Minor Allele MAF
SNP1 A 0.102 A 0.38 A 0.086
SNP2 A 0.102 A 0.38 A 0.086
SNP3 A 0 A 0.0059 A 0.0071
SNP4 A 0.102 A 0.38 A 0.086
SNP5 A 0.102 A 0.38 A 0.086
SNP6 A 0.102 A 0.38 A 0.086
SNP7 G 0.102 G 0.39 G 0.086
SNP8 A 0 A 0.012 A 0
SNP9 A 0.102 A 0.36 A 0.014
SNP10 G 0.102 G 0.38 G 0.086
SNP11 G 0 G 0 G 0
SNP12 T 0.102 T 0.38 T 0.086
SNP13 T 0.034 T 0.14 T 0.036
SNP14 A 0.49 C 0.4 C 0.093
SNP15 C 0.102 C 0.38 C 0.086
SNP16 G 0.102 G 0.38 G 0.086
SNP17 C 0 C 0 C 0
SNP18 G 0.407 G 0.0059 G 0
SNP19 A 0.102 A 0.38 A 0.086
SNP20 T 0 T 0 T 0
indel1 – 0 – 0 – 0
indel2 – 0.102 – 0.38 – 0.086
indel3 + 0.14 – 0.49 + 0.12
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Table 3 Hardy Weinberg Equilibrium in WHWTs SNPs and indels are shown in 5’ to 3’ order top to bottom; 118 WHWT alleles counted
for each marker with 100% call rate. Genotype frequencies are shown as homozygote for minor allele/heterozygote/homozygote for major
allele. For significant deviation from Hardy Weinberg equilibrium the p value is highlighted in red
Marker Minor Allele Group Genotype frequency Observed Heterozygotes Expected Heterozygotes P value
SNP1 A Case 2–1 - 25 0.036 0.163 0.005
Control 0–7 - 24 0.226 0.2 1
SNP2 A Case 2–1 - 25 0.036 0.163 0.005
Control 0–7 - 24 0.226 0.2 1
SNP3 A Case 0–0 - 28 0 0 1
Control 0–0 - 31 0 0 1
SNP4 A Case 2–1 - 25 0.036 0.163 0.005
Control 0–7 - 24 0.226 0.2 1
SNP5 A Case 2–1 - 25 0.036 0.163 0.005
Control 0–7 - 24 0.226 0.2 1
SNP6 A Case 2–1 - 25 0.036 0.163 0.005
Control 0–7 - 24 0.226 0.2 1
SNP7 G Case 2–1 - 25 0.036 0.163 0.005
Control 0–7 - 24 0.226 0.2 1
SNP8 A Case 0–0 - 28 0 0 1
Control 0–0 - 31 0 0 1
SNP9 A Case 2–1 - 25 0.036 0.163 0.005
Control 0–7 - 24 0.226 0.2 1
SNP10 G Case 2–1 - 25 0.036 0.163 0.005
Control 0–7 - 24 0.226 0.2 1
SNP11 G Case 0–0 - 28 0 0 1
Control 0–0 - 31 0 0 1
SNP12 T Case 2–1 - 25 0.036 0.163 0.005
Control 0–7 - 24 0.226 0.2 1
SNP13 T Case 0–3 - 25 0.107 0.101 1
Control 0–1 - 30 0.032 0.032 1
SNP14 A Case 7–11 - 10 0.393 0.494 0.275
Control 9–15 - 7 0.484 0.498 1
SNP15 C Case 2–1 - 25 0.036 0.163 0.005
Control 0–7 - 24 0.226 0.2 1
SNP16 G Case 2–1 - 25 0.036 0.163 0.005
Control 0–7 - 24 0.226 0.2 1
SNP17 C Case 0–0 - 28 0 0 1
Control 0–0 - 31 0 0 1
SNP18 G Case 7–12 - 9 0.429 0.497 0.466
Control 5–12 - 14 0.387 0.458 0.438
SNP19 A Case 2–1 - 25 0.036 0.163 0.005
Control 0–7 - 24 0.226 0.2 1
SNP20 T Case 0–0 - 28 0 0 1
Control 0–0 - 31 0 0 1
indel1 – Case 0–0 - 28 0 0 1
Control 0–0 - 31 0 0 1
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hypoadrenocorticism in cocker spaniels, has also been
reported as protective for diabetes in Border terriers;
however, it was neutral in Labradors, miniature Schnau-
zers, West Highland white terriers and crossbreed dogs
and associated with an increased risk of diabetes in
Samoyeds.
Across eight breeds and three diseases, the same SNPs
and haplotypes have been variously described as confer-
ring risk, being protective or neutral [36, 37]. There are
a number of possible reasons for these findings. Firstly,
these risks may be disease specific with hypoadrenocorti-
cism risks changing differently to those for IMHA or
diabetes or the gene may or may not be involved in the
aetiology and pathogenesis of any specific disease.
The same haplotype could have a different relative risk
profile between different breeds; for example, if haplo-
type 3 is relatively protective to haplotype 8 and haplo-
type 8 is relatively protective to haplotype 12, then
haplotype 8 will appear as either increasing or decreas-
ing risk depending on the other haplotypes present in
the breed and in what proportions. Breed specific gen-
etic backgrounds might also influence the effect of
CTLA4 promoter variation, due to epistasis. A specific
example of epistasis and CTLA4 is known in humans,
between CTLA4 and TNF-alpha. A specific TNF–alpha
variant is only associated with an altered risk of primary
biliary cirrhosis when there is an AA genotype, not AG
or GG, at the − 318 CTLA4 promoter polymorphism
[42]. Breed differences may be similar to those seen in
different ethnic groups in the human population, e.g. dif-
ferent CTLA4 3’UTR (AT) n associations are apparent
in Japanese and Portuguese patients with SLE [43], or
different associations of CTLA4 polymorphisms between
distinct populations with Addison’s disease [18]. The in-
teractions between breed, specific epistasis and disease
are likely to be complex and require deeper genetic ana-
lysis in large cohorts of well phenotyped dogs to
understand.
Although transcription factor-binding sites are not
fully conserved between species [44] cross-species com-
parisons can be used to identify potential regulatory sites
[45], possibly due to conserved core binding motifs [46].
There has been little research undertaken on the nature
of canine response elements and transcription factor
binding characteristics, therefore interpretation of effects
of SNPs on binding sites was undertaken based upon
conserved aspects of promoter biology sourced from the
JASPAR database using the online Transcription Elem-
ent Search System (TESS; www.cbil.upenn.edu/tess) and
literature searches. Since computational methods used
alone can deliver high false positive rates [47, 48] below
we have focussed on selected sites of potential biological
significance.
Similar to the findings for springer spaniels and hypoa-
drenocorticism in this study, SNP13T has previously
been associated with increased risk of diabetes in Labra-
dors [34]; however, this variant was also associated with
a decreased diabetes risk in miniature Schnauzers and
Table 3 Hardy Weinberg Equilibrium in WHWTs SNPs and indels are shown in 5’ to 3’ order top to bottom; 118 WHWT alleles counted
for each marker with 100% call rate. Genotype frequencies are shown as homozygote for minor allele/heterozygote/homozygote for major
allele. For significant deviation from Hardy Weinberg equilibrium the p value is highlighted in red (Continued)
Marker Minor Allele Group Genotype frequency Observed Heterozygotes Expected Heterozygotes P value
indel2 – Case 2–1 - 25 0.036 0.163 0.005
Control 0–7 - 24 0.226 0.2 1
indel3 + Case 2–4 - 22 0.143 0.245 0.066
Control 0–8 - 23 0.258 0.225 1
Table 4 CTLA4 promoter haplotypes present in springer spaniels. Number of each haplotype is shown (with frequency in brackets) for
cases, 2n = 56, and controls, 2n = 114. NaN: not a number; OR: odds ratio; 95% CI: 95% confidence intervals of the OR. p values for
individual 2 × 2 tables are given with significant results coloured red, overall significance p = 0.291
CTLA4 promoter Haplotype Cases
2n (%)
Controls
2n (%)
p OR
95% CI
2 27 (48.2%) 34 (29.8%) 0.0266 2.19 (1.13–4.23)
3 1 (1.78%) 2 (1.75%) 1 1.01 (0.09–11.4)
8 21 (37.5%) 57 (50%) 0.1423 0.6 (0.31–1.15)
10 0 (0%) 1 (0.87%) 1 0
11 0 (0%) 3 (2.63%) 0.5516 0
12 7 (12.5%) 16 (14.0%) 1 0.87 (0.33–2.26)
15 0 (0%) 1 (0.87%) 1 0
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Samoyeds. SNP13 is located at the start of a GATA-1
binding site [49]. GATA-1 has been shown to up-
regulate CTLA4 transcription and to be able to initiate a
substantial component of the Treg transcriptional signa-
ture, when expressed in conjunction with FoxP3 in non-
regulatory murine T cells [50]. CTLA4 promoter SNP14
has not previously been associated with disease risk,
however unusually it was found to change minor allele
status between breeds [36]. SNP14 lies adjacent to a core
SP1 promoter site. A polymorphism in the promoter re-
gion of ICOS in humans is associated with an SP1 site
[51] and SP1 is known to affect CIITA transcription in
dendritic cells [52]. SP1 also appears to bind upstream
of Foxp3 in nTregs, which indicates its potential import-
ance in immune responses. SP1 binding can protect
CpG sites from methylation [53] and the SNP14A
Table 5 CTLA4 promoter haplotypes present in cocker spaniels. Number of each haplotype is shown (with frequency in brackets) for
cases, 2n = 38, and controls, 2n = 102. NaN: not a number; OR: odds ratio; 95% CI: 95% confidence intervals of the OR. p values for
individual 2 × 2 tables are given with significant results coloured red, overall significance p = 0.003
CTLA4 promoter Haplotype Cases
2n (%)
Controls
2n (%)
p OR
(95% CI)
2 0 (0%) 2 (1.96%) 1.0000 0
3 6 (15.7%) 4 (3.92%) 0.0247 4.59 (1.21–17.3)
8 27 (71.0%) 94 (92.1%) 0.0038 0.20 (0.07–0.57)
11 1 (2.63%) 0 0.2714 NaN
12 4 (10.5%) 1 (0.98%) 0.0193 11.8 (1.28–110)
15 0 (0%) 1 (0.98%) 1.0000 0
Table 6 Association of CTLA4 polymorphisms with hypoadrenocorticism in springer spaniels. Markers are as Table 3, 5′ to 3′ order
from top to bottom SNPs and then indels. MAF: minor allele frequency; NaN: not a number; N/A: not calculable; OR: odds ratio; 95% CI:
95% confidence intervals of the OR; Max (T) p value calculated by permutation analysis; FDR: false discovery rate
Marker Minor allele MAF in cases MAF in controls Max (T)
p value
FDR OR (95% CI)
SNP1 A 0.5 0.315 0.026 0.03462 2.16 (1.12–4.17)
SNP2 A 0.5 0.315 0.026 0.03462 2.16 (1.12–4.17)
SNP3 A 0 0.008 1 1 0 (0 - NaN)
SNP4 A 0.5 0.315 0.026 0.03462 2.16 (1.12–4.17)
SNP5 A 0.5 0.315 0.026 0.03462 2.16 (1.12–4.17)
SNP6 A 0.5 0.315 0.026 0.03462 2.16 (1.12–4.17)
SNP7 G 0.535 0.315 0.008 0.03462 2.5 (1.29–4.82)
SNP8 A 0.035 0 0.132 0.1072 N/A
SNP9 A 0.482 0.298 0.027 0.03462 2.19 (1.13–4.23)
SNP10 G 0.5 0.315 0.026 0.03462 2.16 (1.12–4.17)
SNP11 N/A 0 0 1 1 N/A
SNP12 T 0.5 0.315 0.026 0.03462 2.16 (1.12–4.17)
SNP13 T 0.125 0.140 1 1 0.87 (0.33–2.26)
SNP14 C 0.5 0.350 0.071 0.07347 1.85 (0.96–3.54)
SNP15 C 0.5 0.315 0.026 0.03462 2.16 (1.12–4.17)
SNP16 G 0.5 0.315 0.026 0.03462 2.16 (1.12–4.17)
SNP17 N/A 0 0 1 1 N/A
SNP18 G 0 0.008 1 1 0 (0 - NaN)
SNP19 A 0.5 0.315 0.026 0.03462 2.16 (1.12–4.17)
SNP20 N/A 0 0 1 1 N/A
indel1 N/A 0 0 1 1 N/A
indel2 – 0.5 0.315 0.026 0.03462 2.16 (1.12–4.17)
indel3 – 0.375 0.543 0.031 0.0571 0.50 (0.26–0.96)
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polymorphism removes a CpG motif from the canine
CTLA4 promoter.
This is the first association between the CTLA4 pro-
moter indel3 and canine disease, with the presence of a
C at indel3 being the most significantly associated risk
marker for hypoadrenocorticism in cocker spaniels (p =
0.0097) and springer spaniels (p = 0.031). Indel3 is situ-
ated between a potential NFAT binding site [54] and a
putative FoxP3 site [55], which are separated by 12 or 13
bases depending on the indel3 status (Fig. 1). NFAT typ-
ically binds to DNA with a partner, e.g. FoxP3 [56] and
both FoxP3 and NFAT response elements are also lo-
cated close together in the CTLA4 promoter in humans
[55, 57]. In mice, FoxP3 and NFAT co-operate in up-
regulating CTLA4 expression and disrupting interaction
between these two transcription factors impairs CTLA4
transcription, impacting on Treg function [58]. Taking
into consideration previous findings in other species, the
association of SNP16G with canine diabetes mellitus and
hypoadrenocorticism and the association of the C inser-
tion with hypoadrenocorticism in cocker spaniels and
springer spaniels, this small region of the canine CTLA4
promoter is very interesting for further investigation.
SNP7, associated with hypoadrenocorticism in
springer spaniels, is adjacent to a predicted binding site
for T cell factor 1 (TCF-1), one of a family of TCF/
Lymphoid enhancer-binding factor (LEF) transcription
factors forming part of the wnt signalling pathway [59].
TCF is particularly important during thymic develop-
ment [60], which might be mediated by wnt3a [61]. The
wnt signalling pathway, including TCF-1 and LEF-1, can
also modulate mature T cell function, including prolong-
ing regulatory T cell (Treg) survival and therefore, po-
tentially impacting on autoimmunity [61]. Four potential
TCF/LEF sites have been identified within the 800 bp
upstream of the start codon in human CTLA4 [62], one
of which contains the C(− 318) T SNP [63] associated
with altered promoter activity [63, 64] and with suscepti-
bility to Grave’s disease [65], autoimmune pancreatitis
[66] but not diabetes [67, 68]. In one study, when a mel-
anoma cell line was treated with wnt3a, CTLA4 was the
most up-regulated gene, which was proposed to
Table 7 Association of CTLA4 polymorphisms with hypoadrenocorticism in cocker spaniels. Markers are as Table 1, 5′ to 3′ SNPs then
indels top to bottom. MAF: minor allele frequency; NaN: not a number; N/A: not calculable; OR: odds ratio; 95% CI: 95% confidence
intervals of the OR. Max (T) p value calculated by permutation analysis; FDR: false discovery rate
Marker Minor allele MAF in cases MAF in controls Max (T)
p value
FDR OR (95% CI)
SNP1 A 0.158 0.059 0.082 0.09887 3 (0.9–9.9)
SNP2 A 0.158 0.059 0.082 0.09887 3 (0.9–9.9)
SNP3 A 0 0.0098 1 1 0 (0 - NaN)
SNP4 A 0.158 0.059 0.082 0.09887 3 (0.9–9.9)
SNP5 A 0.158 0.059 0.082 0.09887 3 (0.9–9.9)
SNP6 A 0.158 0.059 0.082 0.09887 3 (0.9–9.9)
SNP7 G 0.158 0.059 0.082 0.09887 3 (0.9–9.9)
SNP8 N/A 0 0 1 1 N/A
SNP9 A 0 0.01961 1 1 0 (0 - NaN)
SNP10 G 0.158 0.059 0.082 0.09887 3 (0.9–9.9)
SNP11 N/A 0 0 1 1 N/A
SNP12 T 0.158 0.059 0.082 0.09887 3 (0.9–9.9)
SNP13 T 0.105 0.0098 0.016 0.09887 11.88 (1.2–110)
SNP14 C 0.184 0.059 0.031 0.09887 3.61 (1.1–11.5)
SNP15 C 0.158 0.059 0.082 0.09887 3 (0.9–9.9)
SNP16 G 0.158 0.059 0.082 0.09887 3 (0.9–9.9)
SNP17 N/A 0 0 1 1 N/A
SNP18 N/A 0 0 1 1 N/A
SNP19 A 0.158 0.059 0.082 0.09887 3 (0.9–9.9)
SNP20 N/A 0 0 1 1 N/A
indel1 N/A 0 0 1 1 N/A
indel2 – 0.158 0.059 0.082 0.09887 3 (0.9–9.9)
indel3 + 0.263 0.067 0.0097 0.05783 4.85 (1.6–13.9)
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represent a mechanism of immune evasion [62]. In Jur-
kat and HeLa cell lines, addition of LEF-1 has been
shown to increased CTLA4 promoter activity, with the
-318 T variant consistently more active than the -318C
variant [63].
It is highly likely that some of the promoter variants
identified do not confer any functional consequences for
expression of canine CTLA4. In mice, seven intronic
SNPs and three intronic indels have been found, but
these were not associated with any functional outcomes
[69]. Also, any polymorphisms that segregate with
hypoadrenocorticism could be merely in linkage disequi-
librium with enhancers, silencers, insulators or other
locus control regions [70]. In a large study of the human
CTLA4 region, 108 SNPs were typed, 78 of which were
in a 100 kb CTLA4 LD block, only 23 of these were not
significantly associated with Graves’ disease at p < 0.05
and mathematical modelling was used to determine
which variation was most likely functionally associated
with disease [71]. Given that LD blocks in dogs are
larger than in human beings [72] the possibility of genes
in this region (especially ICOS or CD28) being involved
remains, although a microsatellite marker flanking ca-
nine CD28 was not associated with hypoadrenocorticism
in NSDTRs in one study [33].
Conclusions
This study of canine CTLA4 promoter variants in three
dog breeds adds further detail to previous research and
provides some evidence that CTLA4 may from part of
the susceptibility aetiology of canine hypoadrenocorti-
cism in some breeds. This work supports the belief that
the pathophysiology of hypoadrenocorticism is immune-
mediated. This study represents a further step in unrav-
elling the complex genetics of hypoadrenocorticism and
in establishing a potential role for CTLA4.
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